The DOI matches its Crossref record; 70 of the 73 references it cites were found in a registry or an index.
A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding
Open accessAbstract
A single dose of the serotonin 2A receptor (5-HT2AR) agonist psilocybin can have long-lasting beneficial effects on mood, personality, and potentially on mindfulness, but underlying mechanisms are unknown. Here, we for the first time conduct a study that assesses psilocybin effects on cerebral 5-HT2AR binding with [11 C]Cimbi-36 positron emission tomography (PET) imaging and on personality and mindfulness. Ten healthy and psychedelic-naïve volunteers underwent PET neuroimaging of 5-HT2AR at baseline (BL) and one week (1W) after a single oral dose of psilocybin (0.2-0.3 mg/kg). Personality (NEO PI-R) and mindfulness (MAAS) questionnaires were completed at BL and at three-months follow-up (3M). Paired t-tests revealed statistically significant increases in personality Openness (p uncorrected = 0.04, mean change [95%CI]: 4.2[0.4;∞]), which was hypothesized a priori to increase, and mindfulness (p FWER = 0.02, mean change [95%CI]: 0.5 [0.2;0.7]). Although 5-HT2AR binding at 1W versus BL was similar across individuals (p uncorrected = 0.8, mean change [95%CI]: 0.007 [-0.04;0.06]), a post hoc linear regression analysis showed that change in mindfulness and 5-HT2AR correlated negatively (β [95%CI] = -5.0 [-9.0; -0.9], p FWER= 0.046). In conclusion, we confirm that psilocybin intake is associated with long-term increases in Openness and - as a novel finding - mindfulness, which may be a key element of psilocybin therapy. Cerebral 5-HT2AR binding did not change across individuals but the negative association between changes in 5-HT2AR binding and mindfulness suggests that individual change in 5-HT2AR levels after psilocybin is variable and represents a potential mechanism influencing long-term effects of psilocybin on mindfulness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, psychedelics have been found to increase trait mindfulness, and the skills of nonjudgement, compassion and non-reactivity [56, 57].”
From Mindfulness meditation and psychedelics: potential synergies and commonalities (2023) · cites this paper as [57]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“whereas increased mindfulness capacities have been found to persist up to 3 months (43).”
From Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees (2022) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“A further psychological process which may be of particular salience when discussing therapeutic efficacy for anxiety, and which psychedelics have been repeatedly found to enhance, are mindfulness capacities (10, 22, 23, 42–46).”
From Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees (2022) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“as macrodoses have been associated with increased mindfulness (Madsen et al. 2020;Soler et al. 2016;Uthaug et al. 2019)”
From Psychedelic Microdosing, Mindfulness, and Anxiety: A Cross-Sectional Mediation Study (2023) · cites this paper as Madsen et al. 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
The benefits of being present: Mindfulness and its role in psychological well-being
Brown, K. W., & Ryan, R. M. (2003) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.84.4.822 · Cited by 13,448
Acceptance and commitment therapy: model, processes and outcomes
Hayes, S. C., Luoma, J. B., Bond, F. W., Masuda, A., & Lillis, J. (2006) · Behaviour Research and Therapy · doi:10.1016/j.brat.2005.06.006 · Cited by 6,587
Distribution Theory for Glass's Estimator of Effect Size and Related Estimators
Hedges, L. V. (1981) · Journal of Educational Statistics · doi:10.2307/1164588 · Cited by 5,695
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600493 · Cited by 1,955
Self-citationRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Personality in Adulthood: A Five-Factor Theory Perspective
McCrae, R. R., & Costa, P. T. (2005) · Cited by 1,645
Cited by
Sorted by citations
Items 101–181 of 181
The emotional architecture of the psychedelic brain
Moujaes, F., Rieser, N. M., Belinger, L., Herdener, M., Zahid, Z., & Preller, K. H. (2025) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2025.07.006 · Cited by 5
Multimodal Neuroimaging of the Effect of Serotonergic Psychedelics on the Brain
Frautschi, P. C., Singh, A. P., Stowe, N. A., & Yu, J. J. (2024) · American Journal of Neuroradiology · doi:10.3174/ajnr.a8118 · Cited by 5
Increases in Aesthetic Experience Following Ayahuasca Use: A Prospective, Naturalistic Study
Aday, J. S., Bloesch, E. K., Davis, A. K., Domoff, S. E., Scherr, K. C., Woolley, J. D., & Davoli, C. C. (2024) · Journal of Humanistic Psychology · doi:10.1177/00221678241230609 · Cited by 7
Levin, A. W. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241303599 · Cited by 5
“…in mindfulness in multiple clinical trials and survey studies (Murphy-Beiner and Soar, 2020b; Radakovic et al., 2022), with mindfulness capacities sometimes increasing to levels consistent with those of experienced meditators (Madsen et al., 2020; Soler et al., 2016; Uthaug et al., 2018).”
Orlowski, P., Hobot, J., Ruban, A., Szczypiński, J., & Bola, M. (2024) · Psychophysiology · doi:10.1111/psyp.14583 · Cited by 5
Combinatorial approaches for treating neuropsychiatric social impairment
Don, W., Tsheringla, S., McPartland, J. C., & Allsop, S. A. (2022) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2021.0051 · Cited by 6
A review of psilocybin: chemistry, clinical uses and future research directions
Milliken, E. J. T., Galettis, P., & Martin, J. (2023) · Australian Journal of Chemistry · doi:10.1071/ch23010 · Cited by 5
Psychedelics and Mindfulness: A Systematic Review and Meta-AnalysisPreprint
Radakovic, C., Radaković, R., Peryer, G., & Geere, J. (2021) · doi:10.31234/osf.io/yu7jf · Cited by 5
“The searches identified a total of 1805 records from databases and other sources with a total of 13 studies meeting inclusion criteria (Domínguez-Clavé et al., 2019; Madsen et al., 2020; Mian, Altman, & Earleywine, 2019; MurphyBeiner & Soar, 2020; Polito & Stevenson, 2019; Sampedro et al., 2017; Smigielski et al., 201…”
BackgroundMethodInfluentialMadsen, M. K., Petersen, A. S., Stenbæk, D. S., Sørensen, I. M., Schiønning, H., Fjeld, T., Nykjær, C. H., Larsen, S. M. U., Grzywacz, M. Z., Mathiesen, T., et al. (2022) · medRxiv · doi:10.1101/2022.07.10.22277414 · Cited by 5
“It is possible that psilocybin treatment could be a valuable psychological intervention in patients with CCH or other chronic pain conditions, an effect that may be linked to psilocybin-induced increased mindfulness as we have previously observed in healthy individuals.(20) Although psilocybin overall has a favorable…”
BackgroundSelf-citationPsychedelic Modulation of Excitation/Inhibition Balance: A Dual-Phase Neurodevelopmental Model
Kandilakis, C. L., & Papatheodoropoulos, C. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00892 · Cited by 5
Cherniak, A. D., Granqvist, P., Mikulincer, M., & Wolff, M. (2026) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2026.2644857 · Cited by 4
Continuous flow synthesis of N , N -dimethyltryptamine (DMT) analogues with therapeutic potential
Simoens, A., Dejaegere, A., Vandevelde, M., & Stevens, C. V. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00562g · Cited by 5
LSD: Mechanisms and relevance to the treatment of depression
Bouloufa, A., Delcourte, S., Delannay, T., Rovera, R., Lau, T., Moulédous, L., Dkhissi‐Benyahya, O., Guiard, B. P., & Haddjeri, N. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106407 · Cited by 4
Oblak, A., Hudnik, L. K., Levačić, A., Elersič, K., Pregelj, P., & Bon, J. (2024) · Philosophical Psychology · doi:10.1080/09515089.2024.2393690 · Cited by 5
“However, there is a current initiative to change the legal circum-stances regarding medical research of psychedelics in Slovenia, so going forward, blood samples will very likely be collected from our future participants (as in Kolaczynska et al., 2021; Madsen et al., 2020).”
Psilocybin-Assisted Therapy May Enhance Conservation Values in Patients with Alcohol Use Disorder
Gold, N. D., Pagni, B. A., Petridis, P. D., & Bogenschutz, M. P. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2024.0030 · Cited by 4
Sankar, A., Ziersen, S. C., Ozenne, B., Dam, V. H., Beaman, E. E., Kessing, L. V., Fisher, P. M., Budtz–Jørgensen, E., Knudsen, G. M., Miskowiak, K. W., et al. (2024) · Nature Mental Health · doi:10.1038/s44220-024-00299-x · Cited by 4
“A single dose of psilocybin has shown to be associated with decreases in neuroticism for up to 3 months 34 , and a downregulation of cerebral 5-HT 2A R was proportional to increased mindfulness and openness 35 .”
Self-citationOlsen, A. S., Lykkebo-Valløe, A., Ozenne, B., Madsen, M. K., Stenbæk, D. S., Armand, S., Mørup, M., Ganz, M., Knudsen, G. M., & Fisher, P. M. (2021) · medRxiv · doi:10.1101/2021.12.17.21267992 · Cited by 4
“Psilocybin also induces rapid and lasting positive effects on mood, well-being, and personality (Carhart-Harris et al., 2018; Erritzoe et al., 2018; MacLean et al., 2011; Madsen et al., 2020).”
BackgroundSelf-citationMolecular brain imaging of psychedelic action
Cumming, P. D., Egger, K., & Knudsen, G. M. (2025) · International review of neurobiology · doi:10.1016/bs.irn.2025.02.005 · Cited by 3
Self-citationDavid, J., Berkovich‐Ohana, A., & Dor‐Ziderman, Y. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06792-0 · Cited by 6
“Specifically, psychedelic use is generally associated with an increase in openness (Erritzoe et al. 2018; MacLean et al. 2011; Madsen et al. 2020; Netzband et al. 2020) and a decrease in neuroticism (Erritzoe et al. 2018; Netzband et al. 2020; Weiss et al. 2021).”
InfluentialThe right to privacy in the decriminalisation of psilocybin mushrooms in South Africa
Foster, S. W. (2023) · Law Democracy & Development · doi:10.17159/2077-4907/2023/ldd.v27.1 · Cited by 3
Associations between psychedelic-related and meditation-related variables: A longitudinal study
Simonsson, O., Chaturvedi, S., Hendricks, P. S., Stenfors, C. U. D., Osika, W., Narayanan, J., Palitsky, R., & Goldberg, S. B. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.03.025 · Cited by 3
“However, results have been mixed at longer-term follow-ups and many these studies have lacked a control group (e.g., Domínguez-Clav ´ e et al., 2022; Madsen et al., 2020; Sampedro et al., 2017; Smigielski et al., 2019; Soler et al., 2016, 2018).”
Fitzgerald, P. B., Webb, S. L., Denning, N. C., Dowie, T.-I., Schweickle, M. M., Modak, A., Chan, G., Knight, J., Waldron, M., Gainsford, K., et al. (2025) · medRxiv · doi:10.1101/2025.05.28.25328532 · Cited by 3
Increases in aesthetic experience following ayahuasca use: An open-label, naturalistic studyPreprint
Aday, J. S., Bloesch, E., Davis, A. K., Domoff, S. E., Scherr, K. C., Woolley, J. D., & Davoli, C. C. (2023) · doi:10.31234/osf.io/gd8h2 · Cited by 2
Kerr‐Gaffney, J., Myrtle, S., Askari, F., Bird, C., Modlin, N. L., Young, A. H., & Rucker, J. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811251408769 · Cited by 3
“However, NEO-PI scores reported in previous healthy volunteer studies were also higher than population norms; therefore, differences in openness are unlikely to be the reason for conflicting results (MacLean et al., 2011; Madsen et al., 2020).”
InfluentialDost, D., Benyamina, A., & Karila, L. (2024) · L Encéphale · doi:10.1016/j.encep.2024.02.007 · Cited by 2
Terapia antidepresiboaren azken pausoak: oraina eta geroa
Erkizia-Santamaría, I., Ortega, J. E., & Horrillo, I. (2020) · Osagaiz osasun-zientzien aldizkaria · doi:10.26876/osagaiz.2.2020.311 · Cited by 2
Psilocybin does not induce the vulnerability marker HSP70 in neurons susceptible to Olney’s lesions
Iorgu, A.-M., Vasilescu, A.-N., Pfeiffer, N., Spanagel, R., Mallien, A. S., Inta, D., & Gass, P. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01699-3 · Cited by 2
McCulloch, D. E.-W., Grzywacz, M. Z., Madsen, M. K., Jensen, P. S., Ozenne, B., Armand, S., Knudsen, G. M., Fisher, P. M., & Stenbæk, D. S. (2021) · doi:10.31234/osf.io/xqzu2 · Cited by 2
Self-citationUpdate of the Altered States Database (ASDB): 2022-12-31Preprint
Peters, M., Prugger, J., Dimkov, P. R., & Schmidt, T. T. (2023) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/wdfhg · Cited by 3
david, J., Berkovich‐Ohana, A., & Dor‐Ziderman, Y. (2024) · doi:10.31234/osf.io/tmeb3 · Cited by 2
Lyon, A. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.003.0009 · Cited by 1
Afrooghe, A., Ahmadi, E., Lesani, A., Mehranjani, M. S., Elahi, M. M., Babaei, M., Shayan, M., Shafaroodi, H., Jafari, R. M., Foroumadi, A., et al. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04152-5 · Cited by 1
“It has been previously described that a single dose of psilocybin could produce long-term favorable responses in terms of psychological well-being (Madsen et al. 2020).”
Meshkat, S., Fang, H., Sousa-Ho, R., Zeifman, R. J., Dunkley, B. T., Reichelt, A. C., Zhang, Y., Burback, L., Winkler, O., Greenshaw, A. J., et al. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2024.0039 · Cited by 2
“44,45 However, given that high-doses do not elicit the same cognitive alterations, but have been shown, at least in animal models to reach a level of target engagement at the 5-HT2A receptor, whether these subjective changes can explain microdose psilocybin ’ s potential improvements in psychiatric…”
Psychological Effects Related to Psychedelic Substance Use in the Previous 12 Months
Williams, J. D., & Murphy, P. N. (2025) · European Journal of Psychology Open · doi:10.1024/2673-8627/a000081 · Cited by 1
Herrmann, F. M., Jones, G. M., Low, D. M., Zech, J. M., Carhart-Harris, R. L., & Kettner, H. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.09.007 · Cited by 1
Kirlić, N., Atli, M., Mistry, S. J., Gold, M., & Goodwin, G. M. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002119 · Cited by 1
Lasch, A., Schweikert, T., Dora, E., Kolb, T., Schurig, H. L., & Walther, A. (2023) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2046-5202 · Cited by 1
Lyon, A. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.003.0001 · Cited by 1
Lyon, A. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.003.0005 · Cited by 1
Psychedelic therapy for body dysmorphic disorder
Johnson, S., & Letheby, C. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00200 · Cited by 1
“Multiple controlled studies in healthy volunteers have found that moderate-to-high doses of psilocybin are safe and well-tolerated, with no serious and lasting adverse effects and some evidence suggesting psychological benefits (Carhart-Harris et al., 2012; Griffiths et al., 2006, 2011, 2017; Madsen et al., 2020; Nich…”
BackgroundYaden, D. B., & Newberg, A. B. (2022) · doi:10.1093/oso/9780190665678.003.0017 · Cited by 1
Apud, I. (2023) · Studies in Psychology Estudios de Psicología · doi:10.1080/02109395.2022.2163776 · Cited by 1
“…et al., 2018; Dolder et al., 2016; Erritzoe et al., 2018; R. R. Griffiths et al., 2018; Hysek et al., 2014; Kettner et al., 2021; Lebedev et al., 2016; Lerner & Lyvers, 2006; MacLean et al., 2011; Madsen et al., 2020; Pokorny et al., 2017; Schmid & Liechti, 2018; Watts et al., 2017).”
BackgroundDefence versus Development: A Theory of Defensive and Expansive Self-RegulationPreprint
Rojas‐Hernández, J. (2021) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/2a6yz · Cited by 1
Orlowski, P., Hobot, J., Ruban, A., Szczypiński, J., & Bola, M. (2023) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/pw8sm · Cited by 1
Rossi, G. N. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2020.tde-08022021-150020
McCulloch, D. E.-W., Madsen, M. K., Stenbæk, D. S., Kristiansen, S., Ozenne, B., Jensen, P. S., Knudsen, G. M., & Fisher, P. M. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.10.557
Self-citationAharon-Almagor, A., & Barrett, F. S. (2022) · Research Square · doi:10.21203/rs.3.rs-1529935/v1
Naturalistic Entheogenics: Précis of Philosophy of PsychedelicsPreprint
Letheby, C. (2021) · doi:10.31234/osf.io/ztewb
“Several studies have found that a single psychedelic experience, without any accompanying mindfulness training, can increase these mindfulness-related capacities for anywhere from one week to three months (Heuschkel & Kuypers, 2020; Madsen et al., 2020).”
BackgroundForstmann, M., & Sagioglou, C. (2021) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/2489x
Psilocybin-Based Breakthroughs in Natural Medicine
Harmony, D., Judy, F., & Dochniak, M. J. (2023) · Case Reports and Reviews · doi:10.33425/2693-1516.1021
Sankar, A., Ziersen, S. C., Ozenne, B., Dam, V. H., Beaman, E. E., Kessing, L. V., Fisher, P. M., Budtz–Jørgensen, E., Knudsen, G. M., Miskowiak, K. W., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3255535/v1
Self-citationLyon, A. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.003.0010
Lyon, A. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.003.0011
Lyon, A. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.003.0008
Lyon, A. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.003.0006
Lyon, A. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.003.0012
(2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.002.0006
Lyon, A. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.003.0007
(2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.002.0003
Lyon, A. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.003.0004
What Is Psychedelic Experience?
Lyon, A. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.003.0002
(2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.002.0005
Lyon, A. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780198843757.003.0003
Zeifman, R. J. (2024) · doi:10.32920/26052859.v1 · Cited by 1
Afrooghe, A., Ahmadi, E., Lesani, A., Mehranjani, M. S., Elahi, M. M., Babaei, M., Shayan, M., Shafaroodi, H., Jafari, R. M., Foroumadi, A., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4891179
Exploring the therapeutic convergence of meditation, psychedelics, and MDMA
Dines, J. T. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00435 · Cited by 2
Lasch, A., Schweikert, T., Dora, E., Kolb, T., Schurig, H. L., & Walther, A. (2025) · Nervenheilkunde · doi:10.1055/a-2517-1621
Calin, A., Burlec, A. F., Mircea, C., Macovei, I., Hăncianu, M., & Corciovă, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186613
“Therefore, these steps may provide the necessary foundation for promoting and developing new large-scale research to enable this revolutionary therapy to help people affected by mental disorders that are resistant to conventional treatments [8,12].”
Psilocybin’s effect on human brain synaptic plasticityPreprint
Knudsen, G. M., Johansen, A., Plavén‐Sigray, P., Madsen, M. K., Søndergaard, A., Messell, C., Geisler, M., Nasser, A., McCulloch, D. E.-W., Beliveau, V., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7469144/v1
Self-citationMurphy, R. J., Wardlaw, M., Smith, T., Noorani, T. N., Evans, W., Reynolds, L., Menkes, D. B., Sumner, R. L., & Muthukumaraswamy, S. D. (2025) · Journal of Humanistic Psychology · doi:10.1177/00221678251382624
The Potential Therapeutic Effects of MEAI in the Treatment of Alcohol Use Disorder
Ekhlasi, M., Frytz, A., & Nia, A. B. (2025) · Current Addiction Reports · doi:10.1007/s40429-025-00700-4
“Moreover, according to some studies, psychedelic-enhanced neuroplasticity, which may play a role in their therapeutic effects, is also mediated by activation of the 5-HT2A receptors (5-HT2AR) [40, 41], though other studies suggest an independent mechanism [42].”
Wopfner, A., Beck, T., & Penzenstadler, L. E. (2025) · SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice · doi:10.1024/0939-5911/a000954
The interplay of psychedelic use and meditation in shaping psychological well-being
Krabbe, A., Sikka, P., & Jylkkä, J. (2025) · Consciousness and Cognition · doi:10.1016/j.concog.2025.103977 · Cited by 2
“This may have influenced the results, as previous psychedelic use has been shown to enhance mindfulness traits, amplifying the benefits of meditation (Madsen et al., 2020; Mian et al., 2020; Radakovic et al., 2022; Sampedro et al., 2017; Soler et al., 2016; Uthaug et al., 2019).”
Psychedelics and Centering Prayer
Rajcok, B. (2026) · Pastoral Psychology · doi:10.1007/s11089-026-01306-x
“…example, one neuroimaging study in Denmark (Madsen et al., 2020) used PET scans to investigate how psilocybin affects the brain and asked participants to fill out questionnaires to gauge personality changes, mindfulness, and persisting effects following the use of psilocybin (Madsen et al., 2020).”
InfluentialPsilocybin acutely reduces low-frequency BOLD power and frequency-specific connectivityPreprint
Olsen, A. S., Larsen, K. M., McCulloch, D. E.-W., Ganz, M., Madsen, M. K., Ozenne, B., Knudsen, G. M., Rehman, N., & Fisher, P. M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.09.717379
“Psychedelic compounds such as psilocybin elicit profound changes in perception, cognition, and self-experience (Carhart-Harris et al., 2012; Madsen et al., 2020; McCulloch et al., 2022; Roseman et al., 2017).”
Self-citationClassic psychedelics and personality: An updated systematic review
Vicentini, A. B., de Paula, C. C., Reis, J. A. S., Bouso, J. C., Hallak, J. E. C., & SANTOS, R. G. D. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261449386
“…14 were experimental (Aicher et al., 2024; Barrett et al., 2020; Erritzoe et al., 2018; Griffiths et al., 2018; Holze et al., 2024; Ko et al., 2023; Madsen et al., 2020; McCulloch et al., 2022; Pagni et al., 2025; Rocha et al., 2021; Schmid and Liechti, 2018; Timmermann et al., 2024; Vizeli et…”
InfluentialNeurobiologie der Psychedelika
Schmitz, C., & Adolphi, H. (2026) · Elsevier eBooks · doi:10.1016/b978-3-437-21293-2.00004-6
Lerche, A. S., Kelley, D. P., Benros, M. E., Billac, G. B., Bradley, E., Heifets, B. D., Woolley, J. D., Nishimi, K. M., & O’Donovan, A. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.107033
Investigating molecular and hemodynamic effects of LSD in the human brain
McCulloch, D. E.-W., Larsen, K., Johansen, A., Jensen, K. H. R., Nykjær, C. H., Holze, F., Falck, N. D., Neufeld, V. A., Steenstrup, E., Skov-Andersen, P., et al. (2026) · Nature Neuroscience · doi:10.1038/s41593-026-02462-2 · Cited by 2
Self-citationPsychedelic-Induced Changes in Personality Traits: A Systematic Review
Bartkiewicz, P. A., Baran, W. P., & Lachowska, E. M. (2026) · Roczniki Psychologiczne · doi:10.18290/rpsych2025.0017
“Madsen et al. (2020) used dosage of 0.2–0.3 mg/kg of body mass.”
Influential
Metadata
- Authors
- Madsen, M. K., Fisher, P. M., Stenbæk, D. S., Kristiansen, S., Burmester, D., Lehel, S., Páleníček, T., Kuchař, M., Svarer, C., Ozenne, B., & Knudsen, G. M.
- Affiliations
- University of Copenhagen (DK)
- Copenhagen University Hospital (DK)
- National Institute of Mental Health (CZ)
- Corresponding author
- Knudsen, Gitte M.
- ORCID
- Venue
- European Neuropsychopharmacology
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 33
- Pages
- 71-80
- ISSN
- 0924-977X (ISSN-L)
- OpenAlex
- W3009076589
- Cited by
- 183
- References
- 73
- Citations by year
- 2026: 10 · 2025: 29 · 2024: 34 · 2023: 43 · 2022: 27 · 2021: 31 · 2020: 9
- FWCI
- 10.99
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- European Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc-nd)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
- Funders
- Innovation Fund Denmark (4108-00004B)
- Independent Research Fund Denmark (6110-00518B)
- Ester M. og Konrad Kristian Sigurdssons Dyreværnsfond (850-22-55166-17-LNG)
- Rigshospitalet's Research Council (R130-A5324)
- Lundbeck Foundation (F-61171-19-27, R231-2016-3236)
- Horizon 2020 (746850)
- MICR (VI20172020056)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
- Keywords
- psilocybin, mindfulness, personality, openness to experience, neocortex, serotonin receptor agonists, psychedelic therapy
- MeSH terms
- Adult, Benzylamines, Female, Hallucinogens, Humans, Magnetic Resonance Imaging, Male, Neuropsychological Tests, Personality, Personality Tests, Phenethylamines, Psilocybin, Neocortex, Receptor, Serotonin, 5-HT2A, Positron-Emission Tomography, Young Adult, Mindfulness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
